Prognostic significance of serum antibodies to HPV-16 L1 virus-like particles in patients with invasive cervical cancer.

BACKGROUND Persistent infection with high-risk human papilloma virus (HPV) is a prerequisite for the development of cervical cancer. The prognostic value of HPV-16 capsid antibodies in patients with invasive cervical cancer and its correlation with clinicopathological factors were investigated. PATIENTS AND METHODS Serum samples from 150 patients with invasive cervical cancer and 40 healthy female control subjects were analyzed by ELISA for HPV-specific antibodies to HPV-16 L1 virus-like particles (VLPs). RESULTS HPV-16 L1 antibodies were detectable in 65 out of 150 patients (43.3%) and in 12 out of 40 controls (30.0%). Seropositivity was correlated with prolonged, progression-free (p =0.012) and overall survival (p=0.043). Especially in the early FIGO-stages I and II antibodies to HPV-16 L1, VLPs predicted a better outcome. CONCLUSION Antibodies to HPV-16 L1 capsid protein may be of prognostic value for patients with invasive cervical cancer and lack of HPV-16 L1 antibodies may indicate a group of patients with a poor prognosis.

[1]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[2]  J. Dillner,et al.  Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: Basis for a virus‐like particle ELISA , 2005, Journal of medical virology.

[3]  R. Hilfrich,et al.  Analytical And Quantitativecytology And Histology From The Volume 26, Number 5, October 2004 , 2004, Acta Cytologica.

[4]  M. Schiffman,et al.  Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. , 2003, Journal of the National Cancer Institute. Monographs.

[5]  M. Pawlita,et al.  Human Papillomavirus Type 16 L1 Capsomeres Induce L1-Specific Cytotoxic T Lymphocytes and Tumor Regression in C57BL/6 Mice , 2003, Journal of Virology.

[6]  J. Pintos,et al.  Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer , 2003, International journal of STD & AIDS.

[7]  Y. Taketani,et al.  IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: Case‐control study of cervical intraepithelial neoplasia in Japan , 2003, Journal of medical virology.

[8]  G. Bastert,et al.  Immunocytochemical Detection of HPV High-Risk Type L1 Capsid Proteins in LSIL and HSIL as Compared with Detection of HPV L1 DNA , 2003, Acta Cytologica.

[9]  J. Dillner,et al.  Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. , 2002, Gynecologic oncology.

[10]  N. Christensen,et al.  Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer. , 2002, American journal of obstetrics and gynecology.

[11]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[12]  P. Coursaget,et al.  Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. , 1999, The Journal of general virology.

[13]  S. J. Kim,et al.  HPV-16-related proteins as the serologic markers in cervical neoplasia. , 1998, Gynecologic oncology.

[14]  C. Meijer,et al.  Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. , 1997, Journal of the National Cancer Institute.

[15]  R. Hoover,et al.  Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. , 1996, The Journal of infectious diseases.

[16]  F. Wiklund,et al.  A prospective study on the risk of cervical intra‐epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears , 1996, International journal of cancer.

[17]  David R. Scott,et al.  Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. , 1995, The Journal of infectious diseases.

[18]  V. Moreno,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .